Clinical significance of IDH1, EGFR, p53 and MIB1 in Astrocytoma Patients

Abstract

Gliomas are tumors originating from glial cells, which show a range of aggressiveness depending on grade and stage. Therefore, this study evaluated clinical significance of IDH1, EGFR, p53 and MIB1 in grade I to IV astrocytoma patients. Seventy astrocytoma patients were enrolled in this study. Immunohistochemical localization of IDH1, EGFR, p53 and Ki67 was performed and correlated with clinicopathological parameters. High IDH1 expression was found in 60% of astrocytoma patients which was significantly correlated with histological types(p=0.004) and grade(p=0.004) of astrocytoma tumors. High EGFR expression was found in 30% of astrocytoma patients. A trend of higher incidence of EGFR expression was observed in >15 years age group of patients. High p53 expression was found in 37% of astrocytoma patients which was significantly correlated with histological types(p=0.0001) and histologic grade(p=0.0001) of astrocytoma tumors. A significant higher p53 expression with respect to reduced disease-free survival was observed on univariate survival analysis(p=0.01). MIB1 expression was found in 50% of astrocytoma patients which was significantly correlated with histological types(P=0.0001) and histologic grade(p=0.0001) of astrocytoma tumors. In multivariate survival analysis, p53 expression was entered at step 1. In conclusion High IDH1 and EGFR expressing astrocytoma can be benefitted with IDH1 inhibitors and anti EGFR therapy, respectively. Mutant p53 expression emerged as significant prognostic factor predicting reduce disease free survival indicated need of more effective treatment cause cellular apoptosis in high grade astrocytoma.